Biacore International AB has entered into a collaborative agreement with SmithKline Beecham Pharmaceuticals, whereby the pharmaceutical giant will evaluate Biacore’s new prototype high performance system in preclinical and ADME drug screening studies.The collaboration marks yet another milestone in Biacore’s commitment to providing novel analytical systems to help the pharmaceutical industry increase the flow of high-quality drug leads reaching the clinic.
The collaboration is second in a series of validation deals aimed at fully optimising the new high performance system for applications downstream of high-throughput drug screening.
The first deal was signed with Millennium Pharmaceuticals Inc. in December 1999.
As part of the agreement, SmithKline Beecham will rigorously test the device in studies to measure its utility in generating critical drug discovery data.
“This collaboration, like the deal we recently entered into with Millennium Pharmaceuticals, endorses the undoubted value of our biosensor technology to the drug discovery industry,” said Lars-Goran Andren, Biacore’s President and CEO. He added, “Securing SmithKline Beecham as a validation partner means that we will benefit from the expertise of a major pharmaceutical research effort as we seek to optimise the ability of our new high-performance system to overcome the key bottlenecks downstream of high-throughput screening.” Biacore is a global market leader in affinity-based biosensor technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand.
The technology is protected by a strong patent portfolio.
Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world.
Biacore focuses on drug discovery as the prime area for future growth.